Clinical Trials Logo

Non-Small Cell Lung Cancer clinical trials

View clinical trials related to Non-Small Cell Lung Cancer.

Filter by:

NCT ID: NCT04322890 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

PIKACHU
Start date: April 16, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.

NCT ID: NCT04322617 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer

ATHENA
Start date: March 24, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

This study aims to explore the efficacy of Anlotinib with or without Immune Checkpoint Inhibitor in Standard Chemo-immunotherapy Failed Advanced NSCLC.

NCT ID: NCT04322591 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial

POSEIDON
Start date: March 24, 2020
Phase:
Study type: Observational

This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer.

NCT ID: NCT04322578 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC

CONFIRM
Start date: March 24, 2020
Phase: Phase 2
Study type: Interventional

This study aims to explore the efficacy and safety of Crizotinb or Standard Chemotherapy in Met exon 14 skipping Advanced Non-small Cell Lung Cancer

NCT ID: NCT04317651 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Crizotinib in ALK Rearranged Non-small-cell Lung Cancer

SPECIALK
Start date: May 16, 2019
Phase:
Study type: Observational

This is a multicenter, observational, retrospective cohort study aimed at assessing the efficacy and safety of crizotinib in ALK positive NSCLC treated in real life setting.

NCT ID: NCT04316364 Recruiting - Clinical trials for Non-Small-Cell Lung Cancer

A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC

Start date: July 14, 2020
Phase: Phase 3
Study type: Interventional

This trial is designed to evaluate the efficacy, safety and immunogenicity of neoadjuvant treatment with monoclonal antibody SHR-1316 or placebo in combination with platinum doublet chemotherapy in participants with resectable Stage II, IIIA, or selected IIIB non-small cell lung cancer (NSCLC) followed by adjuvant SHR-1316 or placebo and monitoring.

NCT ID: NCT04316013 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: The VAPOR-C Trial

Start date: July 31, 2020
Phase: Phase 3
Study type: Interventional

VAPOR-C is a randomised study of the impact of IV versus inhaled anaesthesia (propofol versus sevoflurane) and lidocaine versus no lidocaine on duration of disease free survival inpatients with either colorectal or non small cell lung cancer.

NCT ID: NCT04315467 Completed - Lung Cancer Clinical Trials

Intraoperative Imaging of Pulmonary Nodules by SGM-101

Start date: July 8, 2020
Phase: Phase 1
Study type: Interventional

The primary objectives of this study are to assess the sensitivity and specificity of SGM-101 in detecting non-small cell lung carcinomas during surgery when excited by an near-infrared light source utilizing intraoperative imaging.

NCT ID: NCT04314089 Active, not recruiting - Clinical trials for Non-small Cell Lung Cancer

Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)

Start date: June 9, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to determine the maximum tolerated dose of GT103 and investigate the safety and effectiveness of the study drug.

NCT ID: NCT04312308 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

A Study for Identification of Predictive Immune Biomarker for Atezolizumab Therapy in NSCLC Patients

Start date: March 2020
Phase:
Study type: Observational

The study aimed to elucidate predictive immune related biomarker to the responsiveness to the PD-L1 blockade and evaluate the dynamics of immune cells in peripheral blood from NSCLC patients during atezolizumab treatment.